Effectiveness and safety of apixaban versus warfarin in non-valvular atrial fibrillation patients in âreal-worldâ clinical practice

Xiaoyan Li1; Steve Deitelzweig2; Allison Keshishian3; Melissa Hamilton1; Ruslan Horblyuk4; Kiran Gupta1; Xuemei Luo5; Jack Mardekian4; Keith Friend1; Anagha Nadkarni1; Xianying Pan6; Gregory Y. H. Lip7,8 1Bristol-Myers Squibb Company, Lawrenceville, New Jersey, USA; 2Ochsner Clinic Foundation, Department of Hospital Medicine, New Orleans, Louisianna, USA and The University of Queensland School of Medicine, Ochsner Clinical School, New Orleans, Louisianna, USA; 3STATinMED Research, Ann Arbor, Michigan, USA; 4Pfizer, Inc., New York, New York, USA; 5Pfizer, Inc., Groton, Conneticut, USA; 6Bristol-Myers Squibb Company, Wallingford, Conneticut, USA; 7Institute of Cardiovascular Sciences, University of Birmingham, Birmingham, UK; 8Aalborg Thrombosis Research Unit, Department of Clinical Medicine, Aalborg University, Aalborg, Denmark